Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming

doi:10.1126/scitranslmed.aad6100

. 2016 Apr 6;8(333):333ra50.

doi: 10.1126/scitranslmed.aad6100.

Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming

Sebastian Zimmer¹, Alena Grebe², Siril S Bakke³, Niklas Bode¹, Bente Halvorsen⁴, Thomas Ulas⁵, Mona Skjelland⁶, Dominic De Nardo⁷, Larisa I Labzin², Anja Kerksiek⁸, Chris Hempel⁹, Michael T Heneka¹⁰, Victoria Hawxhurst¹¹, Michael L Fitzgerald¹¹, Jonel Trebicka¹², Ingemar Björkhem¹³, Jan-Åke Gustafsson¹⁴, Marit Westerterp¹⁵, Alan R Tall¹⁵, Samuel D Wright¹⁶, Terje Espevik¹⁷, Joachim L Schultze¹⁸, Georg Nickenig¹, Dieter Lütjohann⁸, Eicke Latz¹⁹

Affiliations

¹ Medizinische Klinik und Poliklinik II, University Hospital Bonn, 53105 Bonn, Germany.
² Institute of Innate Immunity, University Hospital Bonn, 53127 Bonn, Germany.
³ Institute of Innate Immunity, University Hospital Bonn, 53127 Bonn, Germany. German Center of Neurodegenerative Diseases (DZNE), 53127 Bonn, Germany. Centre of Molecular Inflammation Research, Norwegian University of Science and Technology, 7489 Trondheim, Norway.
⁴ Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, 0424 Oslo, Norway.
⁵ Genomics and Immunoregulation, Life and Medical Sciences Institute, University of Bonn, 53115 Bonn, Germany.
⁶ Department of Neurology, Oslo University Hospital Rikshospitalet, 0424 Oslo, Norway.
⁷ Institute of Innate Immunity, University Hospital Bonn, 53127 Bonn, Germany. Inflammation Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia. Department of Medical Biology, The University of Melbourne, Parkville, Victoria 3010, Australia.
⁸ Institute of Clinical Chemistry und Clinical Pharmacology, University Hospital Bonn, 53105 Bonn, Germany.
⁹ Addi and Cassi Fund, Reno, NV 89511, USA.
¹⁰ Clinic and Polyclinic for Neurology, University Hospital Bonn, 53105 Bonn, Germany.
¹¹ Lipid Metabolism Unit, Center for Computational and Integrative Biology, Boston, MA 02114, USA.
¹² Medizinische Klinik und Poliklinik I, University Hospital Bonn, 53105 Bonn, Germany. Faculty of Health Sciences, University of Southern Denmark Campusvej 55, DK-5230 Odense M, Denmark.
¹³ Division of Clinical Chemistry, Karolinska Institutet, Huddinge University Hospital, 141 86 Huddinge, Sweden.
¹⁴ Center for Nuclear Receptors and Cell Signaling, University of Houston, Houston, TX 77004, USA.
¹⁵ Department of Medicine, Columbia University, New York, NY 10032, USA.
¹⁶ CSL Behring, King of Prussia, PA 19406, USA.
¹⁷ Centre of Molecular Inflammation Research, Norwegian University of Science and Technology, 7489 Trondheim, Norway.
¹⁸ German Center of Neurodegenerative Diseases (DZNE), 53127 Bonn, Germany. Genomics and Immunoregulation, Life and Medical Sciences Institute, University of Bonn, 53115 Bonn, Germany.
¹⁹ Institute of Innate Immunity, University Hospital Bonn, 53127 Bonn, Germany. German Center of Neurodegenerative Diseases (DZNE), 53127 Bonn, Germany. Centre of Molecular Inflammation Research, Norwegian University of Science and Technology, 7489 Trondheim, Norway. Department of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, MA 01605, USA. eicke.latz@uni-bonn.de.

PMID: 27053774
PMCID: PMC4878149
DOI: 10.1126/scitranslmed.aad6100

Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming

Sebastian Zimmer et al. Sci Transl Med. 2016.

. 2016 Apr 6;8(333):333ra50.

doi: 10.1126/scitranslmed.aad6100.

Authors

Affiliations

¹ Medizinische Klinik und Poliklinik II, University Hospital Bonn, 53105 Bonn, Germany.
² Institute of Innate Immunity, University Hospital Bonn, 53127 Bonn, Germany.
³ Institute of Innate Immunity, University Hospital Bonn, 53127 Bonn, Germany. German Center of Neurodegenerative Diseases (DZNE), 53127 Bonn, Germany. Centre of Molecular Inflammation Research, Norwegian University of Science and Technology, 7489 Trondheim, Norway.
⁴ Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, 0424 Oslo, Norway.
⁵ Genomics and Immunoregulation, Life and Medical Sciences Institute, University of Bonn, 53115 Bonn, Germany.
⁶ Department of Neurology, Oslo University Hospital Rikshospitalet, 0424 Oslo, Norway.
⁷ Institute of Innate Immunity, University Hospital Bonn, 53127 Bonn, Germany. Inflammation Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia. Department of Medical Biology, The University of Melbourne, Parkville, Victoria 3010, Australia.
⁸ Institute of Clinical Chemistry und Clinical Pharmacology, University Hospital Bonn, 53105 Bonn, Germany.
⁹ Addi and Cassi Fund, Reno, NV 89511, USA.
¹⁰ Clinic and Polyclinic for Neurology, University Hospital Bonn, 53105 Bonn, Germany.
¹¹ Lipid Metabolism Unit, Center for Computational and Integrative Biology, Boston, MA 02114, USA.
¹² Medizinische Klinik und Poliklinik I, University Hospital Bonn, 53105 Bonn, Germany. Faculty of Health Sciences, University of Southern Denmark Campusvej 55, DK-5230 Odense M, Denmark.
¹³ Division of Clinical Chemistry, Karolinska Institutet, Huddinge University Hospital, 141 86 Huddinge, Sweden.
¹⁴ Center for Nuclear Receptors and Cell Signaling, University of Houston, Houston, TX 77004, USA.
¹⁵ Department of Medicine, Columbia University, New York, NY 10032, USA.
¹⁶ CSL Behring, King of Prussia, PA 19406, USA.
¹⁷ Centre of Molecular Inflammation Research, Norwegian University of Science and Technology, 7489 Trondheim, Norway.
¹⁸ German Center of Neurodegenerative Diseases (DZNE), 53127 Bonn, Germany. Genomics and Immunoregulation, Life and Medical Sciences Institute, University of Bonn, 53115 Bonn, Germany.
¹⁹ Institute of Innate Immunity, University Hospital Bonn, 53127 Bonn, Germany. German Center of Neurodegenerative Diseases (DZNE), 53127 Bonn, Germany. Centre of Molecular Inflammation Research, Norwegian University of Science and Technology, 7489 Trondheim, Norway. Department of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, MA 01605, USA. eicke.latz@uni-bonn.de.

PMID: 27053774
PMCID: PMC4878149
DOI: 10.1126/scitranslmed.aad6100

Abstract

Atherosclerosis is an inflammatory disease linked to elevated blood cholesterol concentrations. Despite ongoing advances in the prevention and treatment of atherosclerosis, cardiovascular disease remains the leading cause of death worldwide. Continuous retention of apolipoprotein B-containing lipoproteins in the subendothelial space causes a local overabundance of free cholesterol. Because cholesterol accumulation and deposition of cholesterol crystals (CCs) trigger a complex inflammatory response, we tested the efficacy of the cyclic oligosaccharide 2-hydroxypropyl-β-cyclodextrin (CD), a compound that increases cholesterol solubility in preventing and reversing atherosclerosis. We showed that CD treatment of murine atherosclerosis reduced atherosclerotic plaque size and CC load and promoted plaque regression even with a continued cholesterol-rich diet. Mechanistically, CD increased oxysterol production in both macrophages and human atherosclerotic plaques and promoted liver X receptor (LXR)-mediated transcriptional reprogramming to improve cholesterol efflux and exert anti-inflammatory effects. In vivo, this CD-mediated LXR agonism was required for the antiatherosclerotic and anti-inflammatory effects of CD as well as for augmented reverse cholesterol transport. Because CD treatment in humans is safe and CD beneficially affects key mechanisms of atherogenesis, it may therefore be used clinically to prevent or treat human atherosclerosis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: No relevant competing interests.

Figures

**Fig. 1. CD treatment impairs murine atherogenesis**
ApoE^−/− mice were fed a cholesterol-rich diet for eight weeks and concomitantly treated with 2 g CD/ kg body weight or vehicle control by subcutaneous injection twice a week (n=7–8 per group). **(A)** Plasma cholesterol levels. **(B)** Atherosclerotic plaque area relative to total arterial wall area. **(C)** Plaque CC load shown as ratio of crystal reflection area to plaque area. **(D)** Representative images of the aortic plaques obtained by confocal laser reflection microscopy. Macrophages stained with anti-CD68 antibodies (red), reflection signal of CCs (white), nuclei stained with Hoechst (blue). Enlarged area (white boxes). Scale bars indicate 500 μm. **(E)** Plaque cellularity shown as ratio of nuclei to plaque area. **(F)** Plaque macrophage load shown as ratio of CD68 fluorescence area to total plaque area. **(G)** Aortic superoxide production determined by L-012 chemiluminescence. Plasma **(H)** IL-1β, **(I)** TNF-α and **(J)** IL-6 levels. Data are shown as mean + s.e.m., Control vs. CD, unpaired two-tailed Student’s t test; ***p < 0.001, **p < 0.01, *p < 0.05, ns = not significant.

**Fig. 2. CD treatment facilitates regression of murine atherosclerosis**
ApoE^−/− mice were fed a cholesterol-rich diet for eight weeks to induce advanced atherosclerotic lesions. Then the diet was either changed to a normal chow (A–D) or the cholesterol-rich diet was continued (E–H) for another four weeks. Mice were simultaneously treated with 2 g CD/ kg body weight or vehicle control twice a week (n=6–8 per group). **(B, F)** Plasma cholesterol levels. **(C, G)** Atherosclerotic plaque area relative to total arterial wall area. **(D, H)** Plaque CC load shown as ratio of crystal reflection area to plaque area. Data are shown as mean + s.e.m., Control vs. CD, unpaired two-tailed Student’s t test; ***p < 0.001, **p < 0.01, *p < 0.05, ns = not significant.

**Fig. 3. CD interacts with and dissolves extra- and intracellular CCs**
**(A, B)** 1 mg CCs were incubated in 0.5 mM rhodamine labeled CD or PBS as control. **(A)** Representative images obtained by confocal laser reflection microscopy. Scale bar equals 20 μm. **(B)** Quantification of rhodamine fluorescence on CCs by flow cytometry. **(C)** ³H-CC were incubated in CD solutions of indicated concentrations overnight shaking at 37°C. Upon filtration through 0.22 μm filter plates radioactivity was determined in the filtrate (filterable/solubilized) and the retentate (crystalline). **(D, E)** iMacs loaded with 200 μg CC/1×10⁶ cells for 3 h prior to incubation with 1 mM rhodamine labeled CD. **(D)** Quantification of rhodamine fluorescence by flow cytometry. **(E)** Representative images obtained by confocal microscopy; rhodamine labeled CD (red), laser reflection signal (green). Scale bars equal 5 μm. **(F)** Intracellular CC dissolution in BMDMs treated with 10 mM CD or control for indicated times determined by polarization microscopy. Data are shown as mean +/− s.e.m of at least three independent experiments.

**Fig. 4. CD mediates metabolism and efflux of crystal-derived cholesterol**
**(A)** Macrophages loaded with CCs prepared from D₆-cholesterol (D₆-CC) can reduce the amount of free, crystal-derived D₆-cholesterol by three main mechanisms: First, acetyl-CoA acetyltransferase (ACAT1) can catalyze the formation of D₆-cholesteryl esters, the storage form of cholesterol which is deposited in lipid droplets. Second, the mitochondrial enzyme 27-hydroxylase (Cyp27A1) can catalyze the formation of D₅-27-hydroxycholesterol, which can passively diffuse across cell membranes. Third, D₅-27-hydroxycholesterol is a potent activator of LXR transcription factors, which in turn mediate the up-regulation of the cholesterol efflux transporters ABCA1 and ABCG1. **(B, C)** iMacs loaded with 200 μg D₆-CC/1×10⁶ cells for 3 h were treated with 10 mM CD or vehicle control prior to GC-MS-SIM analysis of crystal-derived cholesterol. **(B)** Percentage of esterified D₆-cholesterol in cell and supernatant fractions before CD treatment (control bar) and upon 48 h CD treatment. **(C)** Efflux of D₆-cholesterol into supernatants of D₆-CC-loaded macrophages before CD treatment (control bar) and upon 24 h CD treatment. Gene expression of **(D)** *Abca1* and **(E)** *Abcg1*, and **(F)** protein expression of ABCA1 in BMDMs loaded with 100 μg CC/1×10⁶ cells for 3 h followed by incubation with 10 mM CD or medium control for **(D, E)** 4 h or **(F)** 24 h. Immunoblot in **(F)** is representative of three independent experiments and densitometric analysis of all three experiments is provided for 10 mM CD and presented as ABCA1 expression relative to the loading control β-ACTIN. Data are shown as means + s.e.m. of at least three independent experiments. **(G)** D₅-27-hydroxycholesterol in cell and supernatant fractions of iMacs loaded with 200 μg D₆-CC/1×10⁶ cells for 3 h prior to 48 h treatment with 10 mM CD or medium control determined by GC-MS-SIM. **(H)** 27-hydroxycholesterol in cell and supernatant fractions of iMacs upon 48 h treatment with 10 mM CD or medium control. **(B, C)** Medium vs. CD, unpaired two-tailed Student’s t test; (D–F) CC+Control vs. CC+CD, unpaired two-tailed Student’s t test; **(G, H)** Control vs. CD, unpaired two-tailed Student’s t test; ***p < 0.001, *p < 0.05, ns = not significant.

**Fig. 5. CD induces LXR target gene expression in WT macrophages**
**(A)** BMDMs from WT and LXRα^−/−β^−/− mice loaded with 100 μg CC/1×10⁶ cells for 3 h and incubated with 10 mM CD for 4 h for microarray analysis. GSEA for LXR target gene sets described in Heinz *et al.* (30) (Table S1) was performed on gene expression data. **(B, C)** GSEA results for **(B)** WT and **(C)** LXRα^−/−β^−/− BMDMs presented as volcano plots of normalized enrichment score (NES) and enrichment p-values. Red circles show positively and significantly enriched gene sets (NES>1, p-value<0.05). (D–F) Gene expression of **(D)** *Abca1* and **(E)** *Abcg1*, and **(F)** protein expression of ABCA1 in BMDMs from WT and LXRα^−/−β^−/− mice loaded with 100 μg CC/1×10⁶ cells for 3h followed by incubation with 10 mM CD for **(D, E)** 4 h or **(F)** 24 h. The synthetic LXR agonist T0901317 (10 μM) was used as a positive control for ABCA1 protein induction. Immunoblot in **(F)** is representative of two independent experiments. Data are shown as mean + s.e.m. of two independent experiments. CC+Control vs. CC+CD, unpaired two-tailed Student’s t test; *p < 0.05.

**Fig. 6. CD facilitates RCT *in vivo* and promotes urinary cholesterol excretion**
**(A)** BMDMs from WT or LXRα^−/−β^−/− mice were loaded with 100 μg D₆-CC/1×10⁶ cells and injected into the peritoneum of WT mice. Subsequently, mice were treated subcutaneously with 2 g CD/ kg body weight or vehicle control (n=4 per group). D₆-cholesterol content in **(B)** feces and **(C)** urine collected every 3 h over 30 h post CD injection. Data is shown as total area under the curve of excreted D₆-cholesterol pooled from the mice within a group per time point. **(D)** Urine samples collected from three individual NPC1 patients upon intravenous application of CD for specific treatment of NPC. Urine cholesterol concentration was determined by GC-MS-SIM and normalized to urine creatinine excretion.

**Fig. 7. CD induces cholesterol metabolism and an anti-inflammatory LXR profile in human atherosclerotic carotid plaques**
**(A)** Human atherosclerotic carotid plaques obtained by carotid endarterectomies (n=10) were split into two macroscopically equal pieces and cultured for 24 h with 10 mM CD or control. Half of the plaque tissue was used for mRNA profiling with nCounter analysis system (Nanostring technologies), the other half and the culture supernatant were analyzed by GC-MS-SIM. **(B)** Cholesterol efflux from plaque tissue into supernatants displayed as % of total cholesterol per sample. **(C)** Distribution of 27-hydroxycholesterol relative to cholesterol in plaque and supernatant. **(D)** GOEA of differentially expressed (DE) genes (FC>1.3, p-value<0.05) visualized as GO network, where red nodes indicate GO term enrichment by up-regulated DE genes and blue borders indicate GO term enrichment by downregulated DE genes. Node size and border width represent the corresponding FDR-adjusted enrichment p value (q value). Edges represent the associations between two enriched GO terms based on shared genes, where edge thickness indicates the overlap of genes between neighbor nodes. Highly connected terms were grouped together and were annotated manually by a shared general term. **(E)** Heat map of genes involved in the GO term “Regulation of inflammatory response” (GO:0050727). Color bar indicates fold change. **(F)** Volcano plot of NES and enrichment p-values based on GSEA for the LXR target gene set (Table S3). Red circle indicates positively and significantly enrichment of the LXR target gene set (NES>1, p-value<0.05). **(G)** Top DE genes determined by 3-way ANOVA (FC>1.5, p-value<0.05). LXR target genes are colored in red or blue. **(H)** Gene expression of genes relevant for the NLRP3 inflammasome pathway. Color bar indicates fold change. **(B, C)** Data are shown as mean +/− s.e.m. CD vs. Control, paired two-tailed Student’s t test; ***p < 0.001, *p < 0.05.

**Fig. 8. CD impairs atherogenesis and regulates metabolic and anti-inflammatory processes in an LXR-dependent manner**
LDLR^−/− mice were transplanted with WT, LXRα^−/−β^−/− or MAC-ABC^DKO bone marrow. They were then fed a cholesterol-rich diet for eight weeks and concomitantly treated with 2g CD/ kg body weight or vehicle control twice a week (n=6–8 per group). (A–C) Plasma cholesterol levels of CD- and vehicle-treated animals. (D–F) Atherosclerotic plaque area relative to total arterial wall area. (G–I) Descending aortas of LDLR^−/− mice transplanted with WT and LXRα^−/−β^−/− were used for gene expression analysis by microarray, with subsequent filtration for the genes included in the human plaque mRNA profiling. **(G)** GOEA of differentially expressed (DE) genes (FC>1.3, p-value<0.05) visualized as GO network, where red nodes indicate GO term enrichment by up-regulated DE genes and blue borders indicate GO term enrichment by downregulated DE genes. Node size and border width represent the corresponding FDR-adjusted enrichment p value (q value). Edges represent the associations between two enriched GO terms based on shared genes, where edge thickness indicates the overlap of genes between neighbor nodes. Highly connected terms were grouped together and were annotated manually by a shared general term. **(H)** DE genes determined by 3-way ANOVA (FC>1.3, p-value<0.05) in aortas of LDLR^−/− mice transplanted with WT bone marrow. LXR target genes are colored in red or blue. **(I)** Gene expression of genes relevant for the NLRP3 inflammasome pathway. Color bar indicates fold change. **(A, B)** Data are shown as mean + s.e.m., CD vs. Control, unpaired two-tailed Student’s t test; **p < 0.01, *p < 0.05.

See this image and copyright information in PMC

Comment in

Cardiovascular endocrinology: Sugar drug reverses atherosclerosis.
Holmes D. Holmes D. Nat Rev Endocrinol. 2016 Jun;12(6):310. doi: 10.1038/nrendo.2016.62. Epub 2016 Apr 22. Nat Rev Endocrinol. 2016. PMID: 27109781 No abstract available.
Macrophages: Dissolving cholesterol to unclog arteries.
Leavy O. Leavy O. Nat Rev Immunol. 2016 Apr 28;16(5):274-5. doi: 10.1038/nri.2016.50. Nat Rev Immunol. 2016. PMID: 27121648 No abstract available.

Cited by

Cholesterol binding to VCAM-1 promotes vascular inflammation.
Kennelly JP, Xiao X, Gao Y, Kim S, Hong SG, Villanueva M, Ferrari A, Vanharanta L, Nguyen A, Nagari RT, Burton NR, Tol MJ, Becker AP, Lee MJ, Ikonen E, Backus KM, Mack JJ, Tontonoz P. Kennelly JP, et al. bioRxiv [Preprint]. 2024 Sep 18:2024.09.17.613543. doi: 10.1101/2024.09.17.613543. bioRxiv. 2024. PMID: 39345495 Free PMC article. Preprint.
Impact of Methylated Cyclodextrin KLEPTOSE^® CRYSMEB on Inflammatory Responses in Human In Vitro Models.
Truffin D, Marchand F, Chatelais M, Chêne G, Saias L, Herbst F, Lipner J, King AJ. Truffin D, et al. Int J Mol Sci. 2024 Sep 9;25(17):9748. doi: 10.3390/ijms25179748. Int J Mol Sci. 2024. PMID: 39273695 Free PMC article.
β-Cyclodextrin-based nanoassemblies for the treatment of atherosclerosis.
Ji W, Zhang Y, Shao W, Kankala RK, Chen A. Ji W, et al. Regen Biomater. 2024 Jun 17;11:rbae071. doi: 10.1093/rb/rbae071. eCollection 2024. Regen Biomater. 2024. PMID: 38966400 Free PMC article. Review.
Canonical and non-canonical roles of complement in atherosclerosis.
Maffia P, Mauro C, Case A, Kemper C. Maffia P, et al. Nat Rev Cardiol. 2024 Nov;21(11):743-761. doi: 10.1038/s41569-024-01016-y. Epub 2024 Apr 10. Nat Rev Cardiol. 2024. PMID: 38600367 Review.
Luminol-conjugated cyclodextrin biological nanoparticles for the treatment of severe burn-induced intestinal barrier disruption.
Song Y, Li Y, Hu W, Li F, Sheng H, Huang C, Gou X, Hou J, Zheng J, Xiao Y. Song Y, et al. Burns Trauma. 2024 Mar 3;12:tkad054. doi: 10.1093/burnst/tkad054. eCollection 2024. Burns Trauma. 2024. PMID: 38444636 Free PMC article.

See all "Cited by" articles

References

1. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, Shahawy ME, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJP. ODYSSEY LONG TERM Investigators, Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. N Engl J Med. 2015 doi: 10.1056/NEJMoa1501031. - DOI - PubMed
1. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA. Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators, Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. N Engl J Med. 2015 150315080057008. - PubMed
1. Task Force Members, ESC Committee for Practice Guidelines (CPG) Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt K, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabate M, Senior R, Taggart DP, van der Wall EE, Vrints CJM, Zamorano JL, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Husted S, James SK, Kervinen K, Kristensen SD, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Ryden L, Simoons ML, Steg PG, Timmis A, Yildirir A. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949–3003. Document Reviewers. - PubMed
1. Sheedy FJ, Grebe A, Rayner KJ, Kalantari P, Ramkhelawon B, Carpenter SB, Becker CE, Ediriweera HN, Mullick AE, Golenbock DT, Stuart LM, Latz E, Fitzgerald KA, Moore KJ. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat Immunol. 2013;14:812–820. - PMC - PubMed
1. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nuñez G, Schnurr M, Espevik T, Lien E, Fitzgerald KA, Rock KL, Moore KJ, Wright SD, Hornung V, Latz E. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357–1361. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information
Molecular Biology Databases
- Mouse Genome Informatics (MGI)

[1] Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, Shahawy ME, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJP. ODYSSEY LONG TERM Investigators, Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. N Engl J Med. 2015 doi: 10.1056/NEJMoa1501031. - DOI - PubMed

[2] Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, Shahawy ME, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJP. ODYSSEY LONG TERM Investigators, Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. N Engl J Med. 2015 doi: 10.1056/NEJMoa1501031. - DOI - PubMed

[3] Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA. Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators, Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. N Engl J Med. 2015 150315080057008. - PubMed

[4] Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA. Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators, Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. N Engl J Med. 2015 150315080057008. - PubMed

[5] Task Force Members, ESC Committee for Practice Guidelines (CPG) Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt K, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabate M, Senior R, Taggart DP, van der Wall EE, Vrints CJM, Zamorano JL, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Husted S, James SK, Kervinen K, Kristensen SD, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Ryden L, Simoons ML, Steg PG, Timmis A, Yildirir A. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949–3003. Document Reviewers. - PubMed

[6] Task Force Members, ESC Committee for Practice Guidelines (CPG) Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt K, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabate M, Senior R, Taggart DP, van der Wall EE, Vrints CJM, Zamorano JL, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Husted S, James SK, Kervinen K, Kristensen SD, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Ryden L, Simoons ML, Steg PG, Timmis A, Yildirir A. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949–3003. Document Reviewers. - PubMed

[7] Sheedy FJ, Grebe A, Rayner KJ, Kalantari P, Ramkhelawon B, Carpenter SB, Becker CE, Ediriweera HN, Mullick AE, Golenbock DT, Stuart LM, Latz E, Fitzgerald KA, Moore KJ. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat Immunol. 2013;14:812–820. - PMC - PubMed

[8] Sheedy FJ, Grebe A, Rayner KJ, Kalantari P, Ramkhelawon B, Carpenter SB, Becker CE, Ediriweera HN, Mullick AE, Golenbock DT, Stuart LM, Latz E, Fitzgerald KA, Moore KJ. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat Immunol. 2013;14:812–820. - PMC - PubMed

[9] Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nuñez G, Schnurr M, Espevik T, Lien E, Fitzgerald KA, Rock KL, Moore KJ, Wright SD, Hornung V, Latz E. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357–1361. - PMC - PubMed

[10] Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nuñez G, Schnurr M, Espevik T, Lien E, Fitzgerald KA, Rock KL, Moore KJ, Wright SD, Hornung V, Latz E. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357–1361. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming

Affiliations

Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Molecular Biology Databases

Abstract

Conflict of interest statement

Figures

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Molecular Biology Databases